L-methionine suppresses pathological sequelae of cis-platinum in the rat.

The pathological changes characteristically observed in the kidney, bone marrow, thymus, spleen, and duodenum of the rat given 12.2 mg/kg of cis-platinum (CDDP) ip are reduced or eliminated when a CDDP solution containing a 20-fold excess of L-methionine to cis-platinum is administered. L-Methionine was also effective in reducing the renal toxicity induced by CDDP when given orally 20 min before the iv administration of 7.5 mg CDDP/kg. L-Methionine did not compromise the efficacy of CDDP when the antitumor activity of the combination of L-methionine and CDDP was measured against the Walker 256 carcinosarcoma in the rat. No significant reduction in the antitumor activity of the CDDP resulted from the parenteral administration of L-Methionine when evaluated against the L1210 murine leukemia. The oral administration of L-methionine (500 mg/kg) 30 min after the administration of CDDP has no significant effect on the antitumor activity of CDDP in mice bearing the L1210 murine leukemia. The results suggest that L-methionine may have some practical utility in the control of certain aspects of CDDP toxicity.
AuthorsM A Basinger, M M Jones, M A Holscher
JournalFundamental and applied toxicology : official journal of the Society of Toxicology (Fundam Appl Toxicol) Vol. 14 Issue 3 Pg. 568-77 (Apr 1990) ISSN: 0272-0590 [Print] UNITED STATES
PMID2340984 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Platinum
  • Methionine
  • Creatinine
  • Cisplatin
  • Animals
  • Blood Urea Nitrogen
  • Bone Marrow (pathology)
  • Carcinoma 256, Walker (drug therapy)
  • Cisplatin (antagonists & inhibitors, therapeutic use, toxicity)
  • Creatinine (blood)
  • Female
  • Kidney (pathology)
  • Leukemia L1210 (drug therapy)
  • Methionine (pharmacology)
  • Platinum (pharmacokinetics)
  • Rats
  • Rats, Inbred Strains
  • Spleen (pathology)
  • Thymus Gland (pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: